Do you want to read an article? Please log in or register.
Impact of Genomic Subtype on Intracranial Outcomes in Treatment-naive EGFR mutant NSCLC with Osimertinib (IGnITE)
Lung, Respiratory and Thoracic Cancer
Related content
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
Adv Ther
Girard N, Macouillard P, Byng D, Meng J, Coerts F, Hunter S, Struebing A, Xiong Y, Park S, Haq MI, Tymejczyk O, Chouaid C, Audigier-Valette C, Debieuvre D, Quantin X, Bosquet L, Pérol M
doi: 10.1007/s12325-025-03465-4
Lung, Respiratory and Thoracic Cancer
Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis
Lung Cancer
Alexander M, Itchins M, Felthun J, Nagrial A, Brown LJ, O'Byrne K, Mersiades AJ, Hughes BGM, Warburton L, Kong BY, Moore M, Blinman P, Bowyer S, Clay T, Spelman T, Pavlakis N, Solomon BJ, Kao S
doi: 10.1016/j.lungcan.2025.108854
Lung, Respiratory and Thoracic Cancer
Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study
Lung Cancer
Gomez-Randulfe I, Monaca F, Cantale O, Reale ML, Mrak L, Zullo L, Diaz SS, Bueno MZ, Maridueña Moreno MA, Davis C, Cox S, Lee D, Shah R, Geldart T, Baena J, Benitez JC, Rosario Garcia Campelo MA, Remon J, Planchard D, Galetta D, Tiseo M, Cortinovis D, Metro G, Bria E, Passiglia F, Novello S, Califano R
doi: 10.1016/j.lungcan.2025.108797
Lung, Respiratory and Thoracic Cancer
Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis
Lung Cancer
Hayashi H, Cho BC, Kim YJ, Lee SH, Danchaivijitr P, Alip A, Xiong H, How SH, Chang GC, Yang JC, Yamanaka Y, Nahit Şendur MA, Prabhash K, Azuma K, Akawung A, Fennema E, Tang X, Shah S, Sethi S, Lu S
doi: 10.1016/j.lungcan.2026.109305
Lung, Respiratory and Thoracic Cancer
Outcomes with neoadjuvant osimertinib and/or chemotherapy in patients with EGFR-mutant resectable non-small cell lung cancers
Lung Cancer
Agrawal P, Rotow J, Rocco G, Travis W, Ortiz E, Scalabrino R, LoPiccolo J, Facchinetti F, Kris MG, Yu HA, Jones D, Chaft JE
doi: 10.1016/j.lungcan.2025.108795
ELCC 2026
Lung, Respiratory and Thoracic Cancer
The Italian ATLAS registry study: Real-world outcomes with adjuvant osimertinib in patients with resected EGFR-mutated NSCLC
Lung, Respiratory and Thoracic Cancer
Aumolertinib Versus Osimertinib as First-Line Treatment for EGFR-Mutant Non-Small Cell Lung Cancer: A Retrospective Real-World Multicenter Study
Int J Cancer
Wang J, Qi P, Li J, Wang N, Fu C, Liu L, Li S, Li X, Hou X, Qiao H
doi: 10.1002/ijc.70617
Lung, Respiratory and Thoracic Cancer
Clinical impact of local consolidative therapy in EGFR-mutant metastatic NSCLC: A propensity-matched multicenter analysis
Lung Cancer
Lee EH, Kim MH, Kang DH, Moon J, Kwak SH, Eom JS, Lee JE, Kim CY, Chang YS, Lee SH, Kim EY, Lee CY, Cho J
doi: 10.1016/j.lungcan.2026.109423
Lung, Respiratory and Thoracic Cancer
Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer
Lung Cancer
Sun F, Banwait MK, Singhal S, Herrmann A, Piotrowska Z, Yun K, Bazhenova L, Ullah AT, Guo EW, Wakelee HA, Neal JW, Das MS, Ramchandran KJ, Roy M, Diehn M, Myall NJ
doi: 10.1016/j.lungcan.2025.108747